Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 18:12:979384.
doi: 10.3389/fonc.2022.979384. eCollection 2022.

Hypofractionated concurrent chemoradiotherapy related lymphopenia and its association with survival in locally advanced non-small cell lung cancer patients

FangJie Liu  1   2 , YingJia Wu  1 , JianHui Shao  1 , Bo Qiu  1   2 , SuPing Guo  1 , QiaoTing Luo  1 , JinYu Guo  1   2 , DaQuan Wang  1   2 , Chu Chu  1   2 , Rui Zhou  1   2 , NaiBin Chen  1   2 , XinLei Ai  1   2 , Hui Liu  1   2
Affiliations

Hypofractionated concurrent chemoradiotherapy related lymphopenia and its association with survival in locally advanced non-small cell lung cancer patients

FangJie Liu et al. Front Oncol. .

Abstract

Background: To evaluate longitudinal changes of concurrent chemoradiotherapy (CCRT) related lymphopenia and its association with survival in locally advanced non-small cell lung cancer (LA-NSCLC) patients.

Methods: Total lymphocyte count (TLC) at baseline, weekly intervals during CCRT and monthly intervals up to 12 months after CCRT were documented. The Common Terminology Criteria for Adverse Events version 5.0 was used to grade the severity of lymphopenia. Cox regression analysis was performed to evaluate the association between overall survival (OS) and CCRT related lymphopenia at different timepoints. Logistic regression model was used to determine the clinical factors associated with TLC level.

Results: 381 LA-NSCLC patients treated with definitive CCRT without consolidation therapy (NCT02573506/NCT02577341) between 2011 to 2020 were analyzed. With a median follow-up of 45.8 months, the median OS was 41.0 months for all patients. Univariable analysis demonstrated that the 3 weeks during CCRT Grade (G) 4 lymphopenia (P=0.018), 2 months after CCRT G1-4 lymphopenia (P=0.004), 6 months after CCRT (6m-post-CCRT) G1-4 lymphopenia (P=0.001), and TLC nadir (P=0.020) were significantly associated with poorer OS. Multivariable analysis suggested that 6m-post-CCRT G1-4 lymphopenia (HR 2.614; P=0.041) were one of the independent predictors of OS. Further analysis inferred that radiation dose (OR: 1.328; P=0.005), GTV volume (OR: 1.004; P=0.036), and baseline TLC (OR: 0.288; P=0.001) were associated with 6m-post-CCRT lymphopenia.

Conclusion: The persistent lymphopenia at 6 months after CCRT was an independent prognostic factor of OS in LA-NSCLC patients. Higher radiation dose, larger gross tumor volume and lower baseline TLC were significantly related to 6m-post-CCRT lymphopenia.

Keywords: concurrent chemoradiotherapy; locally advanced non-small cell lung cancer; lymphopenia; overall survival; total lymphocyte count.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Changes of the total lymphocyte count (TLC) at longitudinal timepoints during concurrent chemoradiotherapy (CCRT) and follow-up. Abbreviations: pre-CCRT, the baseline; mid-CCRT, the 3 weeks during CCRT; end-CCRT, the end of CCRT; 2m-post-CCRT, 2 months after CCRT; 6m-post-CCRT, 6 months after CCRT.
Figure 2
Figure 2
The association between overall survival (OS) and 6m-post-CCRT TLC.
Figure 3
Figure 3
The association between progression free survival (PFS) (A) and local control (B) with 6m-post-CCRT TLC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. . Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 69(13):5383–91. doi: 10.1158/0008-5472.Can-08-3845 - DOI - PMC - PubMed
    1. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) (2011) 236(5):567–79. doi: 10.1258/ebm.2011.011007 - DOI - PMC - PubMed
    1. Sellins KS, Cohen JJ. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol (1987) 139(10):3199–206. - PubMed
    1. Venkatesulu BP, Mallick S, Lin SH, Krishnan S. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol (2018) 123:42–51. doi: 10.1016/j.critrevonc.2018.01.003 - DOI - PubMed
    1. Wu ES, Oduyebo T, Cobb LP, Cholakian D, Kong X, Fader AN, et al. . Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol (2016) 140(1):76–82. doi: 10.1016/j.ygyno.2015.11.013 - DOI - PMC - PubMed

LinkOut - more resources